Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

Five drugmakers are due to report Q3 2026 results: Amgen, Pfizer, Moderna, Novo Nordisk and Viatris. Consensus estimates include revenue of $9.95B for Amgen, $16.13B for Pfizer, $888.8M for Moderna, $11.39B for Novo Nordisk and $3.78B for Viatris; the article cites positive earnings-surprise indicators for Pfizer and Viatris, but a -71.32% Earnings ESP for Moderna and -1.82% for Amgen. Expected growth drivers include GLP-1 drugs at Novo Nordisk and respiratory vaccines at Moderna, with product declines and biosimilar erosion posing offsets elsewhere.

Analysis

The key distinction is revenue quality, not the probability of an EPS “beat.” For AMGN, growth in newer products may not translate one-for-one into durable earnings if price concessions and biosimilar erosion outpace volume; the release should be judged on product-level net sales and full-year guidance, not the headline beat. For PFE, a positive estimate signal is a modest near-term edge, but the market needs evidence that newer-product growth can offset legacy-brand pressure without relying on cost actions. VTRS’s developed-market strength is potentially offset by emerging-market weakness and FX; verify constant-currency growth and segment mix before treating a beat as a reacceleration. NVO’s GLP-1 demand is not enough by itself: realized price, access and supply capacity determine whether volume converts to revenue, with Eli Lilly a key competitive read-through. MRNA remains the most asymmetric event: respiratory vaccine uptake could help this quarter, but a seasonal sales bounce would not establish a steadier commercial base.

Near term (this week), sequential reactions will be driven more by guidance and product mix than by small estimate beats. Over 1–3 months, payer access, vaccine uptake and competitive pricing are the key checks; over 6–18 months, biosimilar erosion and the ability of newer portfolios to replace mature-product revenue matter more. Article-supplied ESP figures are noisy pre-event indicators, not independently verified positioning or valuation data. Without prices, options-implied moves and product-level consensus, there is no robust pre-release directional edge. Falsification: guidance cuts, weaker-than-expected net sales in growth products, or continued deterioration in legacy products despite reported beats.

Key Decisions for Investors

• Avoid broad pre-earnings exposure across the five names; binary event risk is high and the supplied data do not establish attractive risk-adjusted entry prices. Reassess after the Nov. 3–6 releases, prioritizing guidance and product-level revenue over EPS surprises.
• Watch PFE versus AMGN after their Nov. 3 reports as a conditional relative-value setup: favor PFE only if newer-product growth supports maintained/improved guidance, and underweight AMGN if growth brands fail to offset mature-product and biosimilar pressure. Do not initiate solely on the ESP difference; compare post-event price reaction and guidance first.
• Keep MRNA as a watch rather than a pre-event short: a weak ESP is not enough to price a downside trade. Consider bearish exposure only if vaccine demand or forward revenue commentary disappoints and the stock fails to stabilize after the release; verify the implied move and liquidity before using options.
• For NVO, monitor price/mix, access and supply commentary against Eli Lilly’s competitive trajectory. A revenue beat without evidence of favorable monetization is not a sufficient long catalyst; downgrade the thesis if guidance or realized revenue per unit weakens.